drugset / Trial / NCT03623321
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.
Timeline
- Start
- 2018-07-17
- Primary completion
- 2023-05-05
- Completion
- 2023-05-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 20 mg | Oral |
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |